Written by Klarity Editorial Team
Published: Mar 2, 2026

If you’ve been considering popular weight loss medications like Wegovy, Ozempic, or Mounjaro but aren’t sure whether you can access them through telehealth, you’re not alone. Millions of Americans are turning to virtual care for obesity treatment—and the good news is that yes, you can legally get these medications through telehealth in most states.
This guide breaks down everything you need to know: how federal and state laws work, which states require in-person visits, who can prescribe these medications virtually, and what to watch out for when choosing a telehealth provider.
Federal law does not require an in-person visit before prescribing GLP-1 weight loss medications like Wegovy, Ozempic, or Mounjaro. These drugs are not controlled substances, which means they fall outside the stricter regulations that apply to medications like Adderall or painkillers.
During the COVID-19 pandemic, telehealth prescribing expanded dramatically—and those flexibilities have largely remained in place. As of December 2025, the DEA continues to allow telehealth prescribing of controlled substances through the end of the year, while non-controlled medications (including all GLP-1 agonists) have always been eligible for telehealth prescribing under federal law.
Bottom line: In most states, a licensed healthcare provider can evaluate you online via video visit and electronically send a prescription to your pharmacy if you qualify medically.
Before diving into state-specific rules, let’s clarify what these medications are and how they work.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications originally developed for type 2 diabetes. They work by:
| Medication | Active Ingredient | FDA Approval | Typical Use |
|---|---|---|---|
| Wegovy | Semaglutide 2.4mg | Chronic weight management (BMI ≥30 or ≥27 with comorbidities) | Weight loss |
| Ozempic | Semaglutide 0.5-1mg | Type 2 diabetes | Often prescribed off-label for weight loss |
| Mounjaro/Zepbound | Tirzepatide | Type 2 diabetes (Mounjaro) / Obesity (Zepbound, approved late 2023) | Weight loss and diabetes management |
All three are non-controlled medications, meaning they don’t carry the same federal restrictions as stimulants or opioids. This is crucial for telehealth access.
Reputable telehealth providers follow FDA-approved criteria:
These aren’t ‘quick fix’ diet pills. They require commitment to a comprehensive weight management plan, including nutrition counseling and regular follow-up.
The Ryan Haight Online Pharmacy Consumer Protection Act (2008) requires an in-person medical evaluation before prescribing controlled substances via telemedicine. This law was designed to prevent online ‘pill mills’ from selling narcotics and stimulants without proper oversight.
However, GLP-1 medications are not controlled substances. There is no federal requirement for an in-person visit before prescribing Wegovy, Ozempic, or Mounjaro through telehealth.
During the pandemic, the DEA waived in-person requirements for controlled medications (like ADHD stimulants and addiction treatment drugs) to maintain healthcare access. That waiver has been extended multiple times—most recently through December 31, 2025.
While this extension primarily affects controlled substances, it reflects a broader federal commitment to telehealth. Congress is also considering legislation (like the TREATS Act) to make some telehealth flexibilities permanent.
For patients seeking weight loss medication: The federal landscape is favorable and stable. You don’t need to worry about sudden policy changes preventing telehealth access to GLP-1 drugs.
While federal law permits telehealth prescribing, each state has its own regulations governing medical practice, prescribing standards, and telehealth requirements.
These states allow telehealth prescribing of GLP-1 medications with no in-person visit required:
Some states require a physical exam before or shortly after starting telehealth treatment:
If your state requires an initial in-person visit, you have options:
The good news? Even in stricter states, ongoing management can typically be handled via telehealth once the initial relationship is established.
Not all healthcare providers have the same prescribing authority. Here’s what you need to know:
All states allow licensed physicians to prescribe GLP-1 medications via telehealth, assuming they’re licensed in the state where the patient is located.
As of December 2025, 34 states plus DC grant NPs full independent practice authority—meaning they can evaluate, diagnose, and prescribe without physician oversight (typically after gaining experience through an initial collaborative period).
States with independent NP practice include:
States requiring NP collaboration with physicians:
PAs can prescribe GLP-1 medications in all states, but they always require some level of physician supervision or collaboration. The degree of autonomy varies by state.
When you use a telehealth service like Klarity Health, you may see an MD, DO, NP, or PA depending on your state and the provider’s availability. All Klarity providers are:
You can feel confident that your prescriber is legally authorized and clinically qualified to manage your weight loss treatment.
Wondering what a virtual weight loss consultation actually looks like? Here’s the typical process with a reputable provider:
Your provider will:
The provider will determine if you’re a good candidate based on:
Not everyone will receive a prescription. If you don’t meet criteria or have safety concerns, your provider will recommend alternatives—this is a sign of quality care, not a limitation of telehealth.
If approved, your provider will:
Your prescription will be sent electronically to your chosen pharmacy. Most states now require e-prescribing for all medications.
Insurance considerations:
At Klarity Health, we work with both insurance and cash-pay patients. Our team helps verify coverage and provides upfront pricing so you know what to expect.
Regular follow-ups (typically monthly for the first few months, then every 2-3 months) include:
The popularity of weight loss medications has unfortunately attracted some bad actors. Protect yourself by avoiding services that:
Legitimate providers conduct thorough evaluations and say ‘no’ when appropriate. If a service promises you’ll get a prescription without proper screening, that’s a major red flag.
Important: The FDA banned retail compounding of semaglutide for weight loss in May 2025 due to safety concerns. Only FDA-approved brand medications should be dispensed through legitimate pharmacies.
Beware of offers for:
Quality care requires:
If a service feels like an online pharmacy with minimal oversight, walk away.
You should be able to verify:
Anonymous or vague provider information is concerning.
Legitimate healthcare providers:
Telehealth access to obesity medications is here to stay, with several positive trends on the horizon:
Medicare recently expanded coverage for obesity counseling, and some private insurers are beginning to cover GLP-1 medications for weight management (though coverage remains inconsistent).
Leading telehealth providers are developing comprehensive programs that combine:
At Klarity Health, we’re committed to this holistic approach. We believe successful weight management requires more than just a prescription—it takes a supportive care team and evidence-based lifestyle strategies.
Absolutely. Telehealth is particularly valuable for patients in areas with limited access to obesity specialists. As long as your provider is licensed in your state, your location within that state doesn’t matter.
Your provider must be licensed in the state where you’re physically located at the time of service. If you move permanently, you’ll need to transition to a provider licensed in your new state. Many national telehealth services (like Klarity) have providers in multiple states to accommodate this.
Generally, no. Most telehealth weight loss programs accept self-referrals. However, coordinating with your primary care doctor is smart—they should be aware of all your medications and can provide valuable continuity of care.
These medications are intended for long-term use. Most patients continue treatment for at least 1-2 years, and many remain on them indefinitely to maintain weight loss. Your provider will work with you to determine the right duration based on your goals and response.
Common side effects (nausea, constipation, stomach discomfort) are usually mild and improve over time. Your telehealth provider can adjust your dose, provide management strategies, or switch medications if needed. Serious side effects are rare but require immediate medical attention—your provider will give you clear guidance on when to seek emergency care.
No. They’re contraindicated for people with:
Your provider will screen for these conditions during your evaluation.
At Klarity Health, we’ve designed our telehealth weight management program with your safety, convenience, and success in mind:
We employ board-certified physicians, experienced nurse practitioners, and physician assistants licensed across all 50 states, ensuring you have access no matter where you live.
Ready to explore whether GLP-1 medications might be right for you? Here’s how to begin:
Review the state-specific table earlier in this article to understand any in-person requirements or special considerations in your state.
Before your appointment, have ready:
Choose a reputable telehealth provider that:
During your visit:
Medication is just one tool. Success requires:
Telehealth has transformed access to evidence-based obesity treatment. If you’ve struggled with weight management and meet clinical criteria, GLP-1 medications prescribed through virtual care could be a safe, effective option.
Remember:
The key is choosing a provider who prioritizes your safety, provides personalized care, and supports you throughout your journey.
Ready to get started? Klarity Health offers convenient, affordable, and expert telehealth weight management services. Our experienced providers are here to help you achieve sustainable weight loss with medical support, transparent pricing, and flexible scheduling that fits your life.
Visit Klarity Health today to schedule your consultation and take the first step toward a healthier you.
This article was researched and fact-checked using current regulatory guidance and medical literature as of December 2025:
DEA and HHS Extend Telemedicine Flexibilities through 2025 – U.S. Drug Enforcement Administration, November 15, 2024. Available at: www.dea.gov
COVID-era telehealth prescribing extended – Axios News, November 18, 2024. Available at: www.axios.com
DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025 – McDermott Will & Emery LLP, November 18, 2024. Available at: www.mwe.com
Changing Regulatory and Reimbursement Landscape for Weight Loss Drugs – Goodwin Procter LLP, March 27, 2024. Available at: www.goodwinlaw.com
Know Your State’s Laws Around Semaglutide – Nextech Systems, April 11, 2025. Available at: www.nextech.com
Research verified as of December 17, 2025. Federal telehealth rules for controlled substances are temporary through December 31, 2025, with extension expected. State laws are continuously evolving; this information reflects the most current regulations available at time of publication.
Find the right provider for your needs — select your state to find expert care near you.